NCT00976495 - Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Dapagliflozin

Tablets, Oral, 10 mg, once daily, 12 weeks

DRUG

Placebo

Tablets, Oral, 0 mg, once daily, 12 weeks

DRUG

Hydrochlorothiazide

Tablets, Oral, 25 mg, once daily, 12 weeks

Trial Locations (12)

Compass Research, Llc, Orlando

Orlando Clinical Research Center, Orlando

Elite Research Institute, Miami

University Of Michigan, Ann Arbor

Zablocki Veterans Affairs Medical Center, Milwaukee

Prism Research, Saint Paul

Torrance Clinical Research, Lomita

Advanced Clinical Res Inst, Anaheim

Memorial Hospital Of Rhode Island, Pawtucket

Local Institution, Toronto

Local Institution, Laval

Local Institution, Groningen